[Home](https://github.com/mm80843/T3.5/blob/pages/index.md) >> Class: [Risk](https://github.com/mm80843/T3.5/tree/pages/docs/Risk/index.md) >> Individual ID:PBN__Risk_430 

# __Expectations for vaccine__

## Articles mentionning the risk

* [Current knowledge of COVID-19: Advances, challenges and future perspectives](https://github.com/mm80843/T3.5/blob/pages/Article/PBN__Article_118.md)

## Category to which it belongs

* [Limited capacity, high demand, waning effectiveness, distribution difficulties, and access disparities hinder efficient vaccination efforts.](https://github.com/mm80843/T3.5/blob/pages/PBNCategory/PBN__PBNCategory_75.md)

## Closest similar item

* [Demand for vaccine development](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1888.md)
* [Difficulty in vaccine distribution](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_423.md)
* [Hesitation to vaccinate](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_519.md)
* [High patient demand for vaccinations](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3118.md)
* [Inadequate vaccine efficacy](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_3031.md)
* [Lack of vaccine or cure](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_861.md)
* [Uncertainty of vaccine effectiveness, time-consuming research process](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1886.md)
* [Vaccine availability, vaccine hesitancy](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_2056.md)
* [Vaccine hesitancy](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_1733.md)
* [Waning efficacy of vaccines](https://github.com/mm80843/T3.5/blob/pages/Risk/PBN__Risk_155.md)

## Description of the risk

The development of effective vaccines against SARS-CoV-2 is a critical measure for long-term protection.

## Is the risk affecting GBN scales

* [No](https://github.com/mm80843/T3.5/blob/pages/ISO_Scale/PBN__ISO_Scale_0.md)

## Mitigations of this risk

* [Continue research and development of vaccines against sars-cov-2.](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_3062.md)
* [Vaccine development](https://github.com/mm80843/T3.5/blob/pages/Mitigation/PBN__Mitigation_598.md)

## Name of the risk

Limited ability to prevent and control the spread of SARS-CoV-2 without effective vaccines.

## People affected by this risk

* [General population](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_9.md)
* [Public health officials](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_310.md)

## Stakeholders who can mitigate this risk

* [Pharmaceutical companies](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_46.md)
* [Researchers](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_2.md)
* [Scientists](https://github.com/mm80843/T3.5/blob/pages/Stakeholder/PBN__Stakeholder_124.md)

## Technologies linked to the risk

* [Clinical trials](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1959.md)
* [Development of various vaccine strategies](https://github.com/mm80843/T3.5/blob/pages/Technology/PBN__Technology_1958.md)

## Type of impact of the risk (according to ISO37100)

* [Governance, empowerment and engagement](https://github.com/mm80843/T3.5/blob/pages/ISO_Purpose/PBN__ISO_Purpose_6.md)

## Type of purpose of the risk (according to ISO37100)

* [Resilience](https://github.com/mm80843/T3.5/blob/pages/ISO_Impact/PBN__ISO_Impact_2.md)

## Type of the risk

* [Physical](https://github.com/mm80843/T3.5/blob/pages/RiskHealth/PBN__RiskHealth_0.md)

## Property: has_RiskType

* [Technological](https://github.com/mm80843/T3.5/blob/pages/RiskType/PBN__RiskType_5.md)

